INOVIO Pharmaceuticals, Inc., a biotechnology company focused on DNA medicines for treating and protecting against HPV-related diseases, cancer, and infectious diseases, has announced its intention to conduct a public offering of its common stock. The offering includes shares and accompanying Series A and Series B warrants, with all securities to be sold by INOVIO. Piper Sandler & Co. will act as the sole book-running manager for the offering. The company has filed a shelf registration statement with the SEC, and the offering will proceed based on market conditions. A preliminary prospectus supplement will be filed with the SEC and made available to the public.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.